Also trades as: SABS (NASDAQ) · $vol 2M
SABSW NASDAQ
SAB Biotherapeutics, Inc.
1W: -89.0%
1M: -92.1%
3M: -90.1%
YTD: -96.5%
1Y: -95.8%
3Y: -97.8%
$0.00
-0.00 (-74.42%)
Credit Risk of going bust: lower than 69% of companies Debt: 1.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down 99%), SAB Biotherapeutics, Inc. would be worth roughly what it owes.
Total debt $5.1M against a stock market value of $279.3M.
Distance to default 7.40 (Merton model): prices to 2026-10-21, balance sheet 2026-06-30, debt counted $2.9M (short-term plus half of long-term), stock volatility 60.6%; Altman Z'' 9.84. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down 99%), SAB Biotherapeutics, Inc. would be worth roughly what it owes.
Total debt $5.1M against a stock market value of $279.3M.
Distance to default 7.40 (Merton model): prices to 2026-10-21, balance sheet 2026-06-30, debt counted $2.9M (short-term plus half of long-term), stock volatility 60.6%; Altman Z'' 9.84. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
19 relationships19
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2021-06-22
Earliest Filing
2025-02-05
Latest Filing
partner: 13
target: 3
acquirer: 2
investor: 1
Counterparties (Filed by SABSW)
19 relationshipsCompanies named in SABSW's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Sanford Health | — | partner | Lease agreement for office and laboratory space | 2025-02-05 | View |
| SAB Biotherapeutics, Inc. | SABSW | partner | Lease agreement for office and laboratory space | 2025-02-05 | View |
| Emergent BioSolutions Inc. | EBS | partner | Partnered to provide contract development and manufacturing services for SAB Biotherapeutics' antibody products. | 2022-11-01 | View |
| Emergent BioSolutions Canada, Inc. | EBS | partner | Wholly-owned subsidiary of Emergent BioSolutions Inc. that entered into manufacturing and licensing agreements with SAB | 2022-11-01 | View |
| Sanford Health | — | partner | Landlord in lease agreement and holder of convertible promissory note | 2022-10-13 | View |
| SAB Biotherapeutics, Inc. | SABSW | partner | Lessee in lease agreement and issuer of convertible promissory note | 2022-10-13 | View |
| Big Cypress Acquisition Corp. | BCYP | acquirer | SPAC acquiring SAB Biotherapeutics and purchasing shares from Radcliffe | 2021-10-12 | View |
| Radcliffe SPAC Master Fund, L.P. | — | investor | SPAC master fund selling shares to BCYP | 2021-10-12 | View |
| SAB Biotherapeutics, Inc. | SABSW | target | Target company in the proposed business combination with BCYP | 2021-10-12 | View |
| Continental Stock Transfer & Trust Company | — | partner | Trustee managing the escrow account for the transaction | 2021-10-12 | View |
| Big Cypress Acquisition Corp. | — | acquirer | Parent company entering into a merger agreement and earnout escrow arrangement. | 2021-08-16 | View |
| SAB Biotherapeutics, Inc. | SABSW | target | Target company being acquired in the merger agreement. | 2021-08-16 | View |
| Shareholder Representative Services LLC | — | partner | Stockholder Representative appointed to represent Company Stockholders in the escrow agreement. | 2021-08-16 | View |
| Continental Stock Transfer & Trust Company | — | partner | Escrow Agent appointed to hold and distribute Earnout Shares. | 2021-08-16 | View |
| Big Cypress Holdings LLC | — | partner | Sponsor party and holder of Parent Shares and Warrants | 2021-06-22 | View |
| Big Cypress Acquisition Corp. | — | partner | Parent company entering Merger Agreement | 2021-06-22 | View |
| SAB Biotherapeutics, Inc. | SABSW | target | Target company in the Merger Agreement | 2021-06-22 | View |
| Big Cypress Merger Sub Inc. | — | partner | Wholly owned subsidiary of Parent entering Merger Agreement | 2021-06-22 | View |
| Ladenburg Thalmann & Co. Inc. | — | partner | Sponsor party and holder of Parent Shares and Warrants | 2021-06-22 | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR